title: Standard and intermediate risk acute lymphoblastic leukemia in Poland: a report of the Polish Children's Leukemia/Lymphoma Study Group.
abstract: A total of 527 children with acute lymphoblastic leukaemia (ALL) from the most frequent risk groups: standard risk group (SRG) and intermediate risk group (IRG) were treated between 1987 and 1991 according to an intensified treatment program (based on the BFM protocol) including the use of an intermediate dose of methotrexate in the IRG. A comparison of the treatment results in this group from 513 children treated between 1981 and 1987 indicates that the chance for a 6 year event-free survival has increased to 73% (previously 55%).
authors.affiliation: University School of Medicine, Poznań, Poland.
authors.forename: U
authors.initials: U
authors.lastname: Radwanska
authors.forename: D
authors.initials: D
authors.lastname: Michalewska
authors.forename: P
authors.initials: P
authors.lastname: Kolecki
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: J
authors.initials: J
authors.lastname: Boguslawska-Jaworska
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: R
authors.initials: R
authors.lastname: Cyklis
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: M
authors.initials: M
authors.lastname: Ochocka
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D018572:Disease-Free Survival; D006801:Humans; D011044:Poland / Q000453:epidemiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents